LEAD PARTNER
Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through the Company’s unparalleled sensitivity and flexibility. Its industry-leading Simoa® precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding, management and patient care in neurology, oncology, immunology, cardiology and infectious disease for nearly two decades.
EXPERTISE PARTNERS
Answer ALS
Answer ALS is the single largest & most comprehensive ALS research project in history, producing more ALS data than has ever been amassed, while openly sharing with the global research community. The program coordinates with over 20 institutions, establishing a critical foundation for new clinical trials and developing new ways to categorize ALS patients to identify specific druggable pathways in an effort to make ALS a treatable disease. Since opening the Answer ALS data repository, Neuromine, in 2021, over 300 independent ALS research projects have begun worldwide from free access to the rich data and available samples.
Alamar Biosciences
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels in liquid biopsy samples. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method reducing background signal and increasing sensitivity and dynamic range compared with standard approaches. The NULISA Platform allows for a fully automated workflow with the ARGO™ System enabling less than 30 minutes hands-on time from sample to data.
Neurizon Therapeutics
Neurizon Therapeutics Limited, formerly known as PharmAust, is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.
PROGRAM PARTNERS
Unlearn Ai
Unlearn is a San Francisco-based technology company pioneering generative machine learning methods to eliminate trial and error in medicine. Unlearn’s technology using patient digital twins is regulatory-qualified and used by leading global pharmaceutical companies to run AI-powered clinical trials that reach full enrollment faster and bring new treatments to patients sooner.
Elixirgen Scientific
Elixirgen Scientific’s purpose is to be at the forefront of medical innovation by harnessing the potential of iPSC differentiation technology. We exist to create limitless opportunities for advancing drug discovery and revolutionizing cell therapy across a multitude of diseases, including Alzheimer’s Disease, Parkinson’s Disease, rare neurodegenerative diseases, and many more. We are dedicated to delivering state-of-the-art, tailor-made solutions to empower the pharmaceutical industry towards the next great discovery.
INDUSTRY PARTNERS
ALS TDI
The ALS Therapy Development Institute (ALS TDI) is world’s largest non-profit research institute dedicated solely to ALS. To help accelerate global research and foster collaboration, we developed the ARC Data Commons. This platform allows researchers to easily explore de-identified data from our ALS Research Collaborative (ARC), the longest-running natural history study in ALS. This invaluable resource will enhance understanding of ALS patient subsets and fuel the discovery of potential treatments
INNOVATION PARTNERS
BrainXell
BrainXell provides high-purity, iPSC-derived human neurons and glia for research and development with a focus on drug discovery. Utilizing proprietary technology, we generate high-purity, subtype-specific neurons that mature rapidly and are quickly and easily ready for a variety of assays. Multiple neuron subtypes relevant to a range of disorders are available. Additionally, each neuron subtype can be made in custom batches from 50 million to 10 billion neurons from unique iPSC lines. We are dedicated to delivering the highest quality products for off-the-shelf neurons and custom service projects.
HOSTING PARTNER
Atlantic Research Group
ARG is a contract research organization focused on oncology, immunology, and neurology, providing comprehensive clinical program development services ranging from planning to commercialization, achieving over 50 market authorizations to date. Founded in 2004 with the vision that every project should be highly individualized, ARG has experienced consistent growth across the globe, expanding our range to include drug and device strategic consulting, clinical trial management services, as well as clinical data and analytic solutions. ARG uses first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.
EXHIBITION PARTNERS
Transpharmation
Transpharmation is an accredited preclinical contract research organization specializing in translational pharmacology across various therapeutic areas. We offer neuroscience expertise, utilizing behavioral and molecular assays to help clients benchmark compounds. With extensive experience in antibiotic treatments and diet manipulations, we study their effects on the microbiome. Committed to on-time data delivery and providing flexible, customized solutions, we support clients in optimizing preclinical assets for the development of life-changing medicines
Anatomic Inc.
Anatomic Incorporated is the global leader in scalable production of high-purity motor neurons in just 7 days and Schwann cell precursors in 9 days from pluripotent stem cells, using only small molecules and growth factors. All cells are validated for purity and function, with plug-and-play protocols designed for screening and disease modeling. Custom differentiations from patient-derived lines—including ALS, CMT, and other neurological disorders—can be completed within 1–2 months and co-cultured for advanced model systems.
Axol Biosciences
Axol Bioscience is the leading manufacturer of functional iPSC-derived cells and provider of outsourced services to support ALS drug discovery programs. We manufacturer functional iPSC-derived motor neurons, microglia and astrocytes, building co-culture model systems with relevant endpoints. iPSCs? What can we do to help.
iXCells Biotechnologies
iXCells Biotechnologies is a cell biology and cell technology company dedicated to providing innovative pre-clinical drug discovery solutions and disease relevant cellular models, enabling technologies and services to the academic, biotech and pharma communities to accelerate drug discovery. We offer high quality primary and iPSC-derived cells, custom iPSC services, functional bioassay development and execution. With a network of collaborators, we continue to make discoveries and expand our product offerings as a leader in the marketplace.
EVENT PARTNERS
Catalent
Zydis® orally disintegrating tablet (ODT) technology creates a unique, freeze-dried oral solid dosage form that disperses almost instantly in the mouth, without water. With more than 35 products launched in 60+ countries, Zydis is the world’s fastest and best-in-class ODT. Zydis has advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience, particularly within certain patient populations such as geriatrics, pediatrics and patients suffering from dysphagia. Catalent’s 250,000-square-foot site in Swindon, U.K., houses the Zydis development and manufacturing operation, which produces over 1.2 tablets annually.
NeuroSpector
Neurospector accelerates preclinical drug development for ALS, FTD, and other neurological disorders with 20+ years of academic expertise in neuronal communication. We provide customized research services using predictive human motor neurons from patient and gene-edited IPSCs, advanced neuronal function read-outs such as live microscopy and patch-clamp techniques, and extensive cell viability assays. Our co-culture systems with human muscles and astrocytes offer unparalleled insights into drug efficacy, driving innovation in therapy development and neuroscience research.
Project Mosaic
Project Mosaic is a collaborative R&D effort working to accelerate successful ALS drug development by equipping drug makers with a new class of patient-specific, sporadic ALS disease models (“Neurobiopsies™”) designed to enable precision drug development.
MEDIA PARTNER
ALS News Today
ALS News Today shares credible, up-to-date science-backed news and information. They foster inclusive and supportive communities where patients and caregivers share experiences and access valuable resources. Over 50% of the Bionews team has a personal connection to rare diseases, fueling their dedication and understanding.